Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.46 |
| ▸ | MTOR | P42345 | 4/20 | 0.39 |
| ▸ | PRKDC | P78527 | 3/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9284829 | 0.89 | PIK3CA (0.46) | PIK3CDPIK3CAPIK3CGPIK3CBMTOR | |
| SCHEMBL9274132 | 0.88 | PIK3CA (0.42) | PIK3CDPIK3CAPIK3CGPIK3CBMTOR | |
| SCHEMBL9280334 | 0.88 | PIK3CA (0.46) | PIK3CDPIK3CAPIK3CGPIK3CBMTOR | |
| SCHEMBL9278081 | 0.88 | PIK3CD (0.43) | PIK3CDPIK3CAPIK3CGPIK3CBMTOR | |
| SCHEMBL16476835 | 0.87 | PIK3CA (0.46) | PIK3CDPIK3CAPIK3CGPIK3CBMTOR | |
| SCHEMBL9279553 | 0.86 | PIK3CA (0.41) | PIK3CDPIK3CAPIK3CGPIK3CBMTOR | |
| SCHEMBL9288017 | 0.86 | PIK3CA (0.45) | PIK3CDPIK3CAPIK3CGPIK3CBMTOR | |
| SCHEMBL9278074 | 0.86 | PIK3CA (0.44) | PIK3CDPIK3CAPIK3CGPIK3CBMTOR | |
| SCHEMBL9281817 | 0.86 | PIK3CA (0.41) | PIK3CDPIK3CAPIK3CGPIK3CBMTOR | |
| SCHEMBL9286773 | 0.85 | PIK3CA (0.42) | PIK3CDPIK3CAPIK3CGPIK3CBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140005172-A1 | Benzoxazepines as Inhibitors of PI3K/M TOR and Methods of Their Use and Manufacture | ELELIXIS, INC. (US) | 2014-01-02 | — | — | US | claimed |
| EP-2643319-A1 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-10-02 | — | — | EP | claimed |
| WO-2012074869-A1 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-06-07 | — | — | WO | claimed |
| US-20140005172-A1 | Benzoxazepines as Inhibitors of PI3K/M TOR and Methods of Their Use and Manufacture | ELELIXIS, INC. (US) | 2014-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005172-A1 | Benzoxazepines as Inhibitors of PI3K/M TOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3R2 | PIK3CD 9/4885PIK3CA 4/4885PIK3CG 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.